Hainan Shuangcheng Pharmaceut Asset Resilience Ratio
Hainan Shuangcheng Pharmaceut asset resilience ratio. Hainan Shuangcheng Pharmaceut (002693) has an Asset Resilience Ratio of 0.69% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 002693 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Hainan Shuangcheng Pharmaceut (2014–2025)
Asset resilience ratio of Hainan Shuangcheng Pharmaceut from 2014 to 2025. This chart shows how Hainan Shuangcheng Pharmaceut's Asset Resilience Ratio has changed over time. Read 002693 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Hainan Shuangcheng Pharmaceut's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Hainan Shuangcheng Pharmaceut balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥5.61 Million | 0.69% |
| Total Liquid Assets | CN¥5.61 Million | 0.69% |
Asset Resilience Insights
- Limited Liquidity: Hainan Shuangcheng Pharmaceut maintains only 0.69% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hainan Shuangcheng Pharmaceut Industry Peers by Asset Resilience Ratio
Compare Hainan Shuangcheng Pharmaceut's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Hainan Shuangcheng Pharmaceut Asset Resilience Ratio by Year (2014–2025)
Hainan Shuangcheng Pharmaceut asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Hainan Shuangcheng Pharmaceut.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.01% | CN¥46.43K ≈ $6.79K |
CN¥825.78 Million ≈ $120.84 Million |
+0.01pp |
| 2024-12-31 | 0.00% | CN¥2.83K ≈ $413.53 |
CN¥783.87 Million ≈ $114.70 Million |
-3.55pp |
| 2023-12-31 | 3.55% | CN¥28.52 Million ≈ $4.17 Million |
CN¥803.25 Million ≈ $117.54 Million |
-11.14pp |
| 2022-12-31 | 14.69% | CN¥133.81 Million ≈ $19.58 Million |
CN¥911.02 Million ≈ $133.31 Million |
+8.20pp |
| 2021-12-31 | 6.48% | CN¥55.40 Million ≈ $8.11 Million |
CN¥854.56 Million ≈ $125.05 Million |
-3.90pp |
| 2020-12-31 | 10.38% | CN¥94.25 Million ≈ $13.79 Million |
CN¥907.68 Million ≈ $132.82 Million |
+4.83pp |
| 2019-12-31 | 5.55% | CN¥52.80 Million ≈ $7.73 Million |
CN¥950.98 Million ≈ $139.16 Million |
-6.94pp |
| 2018-12-31 | 12.50% | CN¥139.98 Million ≈ $20.48 Million |
CN¥1.12 Billion ≈ $163.93 Million |
+1.80pp |
| 2017-12-31 | 10.69% | CN¥147.25 Million ≈ $21.55 Million |
CN¥1.38 Billion ≈ $201.52 Million |
+10.26pp |
| 2016-12-31 | 0.43% | CN¥5.00 Million ≈ $731.66K |
CN¥1.17 Billion ≈ $170.55 Million |
+0.21pp |
| 2015-12-31 | 0.22% | CN¥3.37 Million ≈ $493.14K |
CN¥1.55 Billion ≈ $226.84 Million |
-40.06pp |
| 2014-12-31 | 40.27% | CN¥380.00 Million ≈ $55.61 Million |
CN¥943.54 Million ≈ $138.07 Million |
-- |
About Hainan Shuangcheng Pharmaceut
Hainan Shuangcheng Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical injections, solid preparations, and raw materials in China and internationally. The company offers products for oncology and immune, alimentary canal, heart and cerebral, and vessels and metabolism. It also provides Bivalirudin, Epitifibatide, and Thymalfaxin for injection; Pre… Read more